Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac
暂无分享,去创建一个
Jürgen B. Bulitta | Stephan Schmidt | Vera Lucia Lanchote | E. Donadi | T. Dalla Costa | S. Schmidt | J. Bulitta | Carolina Miranda Silva | Adriana Rocha | Eduardo Tozatto | Lucienir Maria Silva | Eduardo Antônio Donadi | Teresa Dalla Costa | A. Rocha | V. Lanchote | L. M. Silva | Carolina de Miranda Silva | E. Tozatto
[1] C. Pace-Asciak,et al. RESOLUTION OF ETODOLAC AND ANTIINFLAMMATORY AND PROSTAGLANDIN SYNTHETASE INHIBITING PROPERTIES OF THE ENANTIOMERS , 1984 .
[2] S. Davis,et al. Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .
[3] C. Demerson,et al. Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid): a potent antiinflammatory drug. Conformation and absolute configuration of its active enantiomer. , 1986, Journal of medicinal chemistry.
[4] M. Cayen,et al. Disposition and biotransformation of 14C-etodolac in man. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.
[5] F. Jamali,et al. Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans. , 1988, Journal of pharmaceutical sciences.
[6] F. Jamali,et al. The pharmacokinetics of etodolac enantiomers in the rat. Lack of pharmacokinetic interaction between enantiomers. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[7] F. Jamali,et al. Stereoselective Disposition of Etodolac Enantiomers in Synovial Fluid , 1991, Journal of clinical pharmacology.
[8] F. Jamali,et al. The Stereoselective Pharmacokinetics of Etodolac in Young and Elderly Subjects, and After Cholecystectomy , 1992, Journal of clinical pharmacology.
[9] F. Jamali,et al. Etodolac Clinical Pharmacokinetics , 1994, Clinical pharmacokinetics.
[10] S. Iacobelli,et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. , 1994, The Journal of pharmacology and experimental therapeutics.
[11] K. Mccarroll,et al. Comparative study of ibuprofen lysine and acetaminophen in patients with postoperative dental pain. , 1995, Clinical therapeutics.
[12] K. Glaser,et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. , 1995, European journal of pharmacology.
[13] F. Lapicque,et al. Albumin binding sites for etodolac enantiomers. , 1996, Chirality.
[14] R. Brugger,et al. Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases , 1997, British journal of pharmacology.
[15] R. Jones,et al. Etodolac: An overview of a selective COX-2 inhibitor , 1999, InflammoPharmacology.
[16] J. Vane,et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[17] S. Cooper,et al. Conventional and extended-release etodolac for postsurgical dental pain. , 1999, Clinical therapeutics.
[18] J. Boni,et al. Pharmacokinetic and Pharmacodynamic Action of Etodolac in Patients after Oral Surgery , 1999, Journal of clinical pharmacology.
[19] Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. , 2001, British journal of clinical pharmacology.
[20] R Gordon,et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. , 2001, The Journal of pharmacology and experimental therapeutics.
[21] Y. Ohno,et al. Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[22] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[23] G. Sarosi,et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. , 2004, Gastroenterology.
[24] C. Brideau,et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors , 1996, Inflammation Research.
[25] N. Holford,et al. Models for describing absorption rate and estimating extent of bioavailability: Application to cefetamet pivoxil , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[26] M. Danhof,et al. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. , 2005, Rheumatology.
[27] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[28] Meindert Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.
[29] K. Hamada,et al. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. , 2008, Urology.
[30] Robert J. Bauer,et al. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples , 2007, The AAPS Journal.
[31] I. Bartal,et al. Perioperative Use of β-blockers and COX-2 Inhibitors May Improve Immune Competence and Reduce the Risk of Tumor Metastasis , 2008, Annals of Surgical Oncology.
[32] R. Borojevic,et al. Racemic Etodolac is cytotoxic and cytostatic for B-cell precursor acute lymphoblastic leukemia cells. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[33] U. Holzgrabe,et al. New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics , 2009, Antimicrobial Agents and Chemotherapy.
[34] M. El-Nabarawi,et al. Polymeric Surfactant Based Etodolac Chewable Tablets: Formulation and In Vivo Evaluation , 2010, AAPS PharmSciTech.
[35] H. Tokuda,et al. Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis. , 2010, Bioorganic & medicinal chemistry letters.
[36] H. Mönnikes,et al. Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[37] Dion R. Brocks,et al. Multiple Peaking Phenomena in Pharmacokinetic Disposition , 2010, Clinical pharmacokinetics.
[38] T. Post,et al. Disease Progression Analysis: Towards Mechanism-Based Models , 2011 .
[39] K. Hasegawa,et al. Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers , 2011, Archives of Gynecology and Obstetrics.
[40] Jurgen B. Bulitta,et al. Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models , 2011, The AAPS Journal.
[41] N. Inoue,et al. The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety. , 2011, Biological & pharmaceutical bulletin.
[42] Jurgen Bernd Bulitta,et al. Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT , 2011, The AAPS Journal.
[43] D. M. van der Heijde,et al. Safety of Nonsteroidal Antiinflammatory Drugs and/or Paracetamol in People Receiving Methotrexate for Inflammatory Arthritis: A Cochrane Systematic Review , 2012, The Journal of Rheumatology. Supplement.
[44] I. Hewala,et al. Enantioselective HPLC-DAD method for the determination of etodolac enantiomers in tablets, human plasma and application to comparative pharmacokinetic study of both enantiomers after a single oral dose to twelve healthy volunteers. , 2014, Talanta.
[45] K. Brune,et al. New insights into the use of currently available non-steroidal anti-inflammatory drugs , 2015, Journal of pain research.
[46] R. Altman,et al. PharmGKB summary: ibuprofen pathways , 2015, Pharmacogenetics and genomics.
[47] E. Donadi,et al. Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics. , 2016, Journal of pharmaceutical and biomedical analysis.
[48] Lena Jaeger,et al. Analytical Profiles Of Drug Substances And Excipients , 2016 .